跳至主要内容
临床试验/ACTRN12623000340639
ACTRN12623000340639招募中3 期

Budesonide versus prednisolone after liver transplantation: a phase 3, open label, non-inferiority randomised controlled trial

Austin Health0 个研究点目标入组 100 人开始时间: 2023年3月31日最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
Austin Health
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • All adult (age 18 years or over) patients accepted for liver transplantation at Austin Health.

排除标准

  • - Strong medical rationale for a corticosteroid-free protocol (e.g. severe psychiatric comorbidities, high risk of infection) as determined by the Liver Transplant Multidisciplinary Team
  • - Patient with autoimmune hepatitis
  • - Corticosteroid dependency prior to trial enrolment
  • - Patients receiving multi-visceral organ transplantation
  • - Previous liver transplant recipient requiring redo liver transplant
  • - Portosystemic shunt >15mm in diameter on imaging which will reduce budesonide first pass metabolism
  • - Concurrent use of medications that are significant cytochrome P450 3A4 inhibitors (e.g. erythromycin, clarithromycin, verapamil, diltiazem) which will reduce budesonide first pass metabolism
  • - Unable to take medications enterally (either orally or through tube feeding) by day 3 post liver transplant
  • - Patients unable to understand written English sufficiently to read PICF or have no carer to assist them with adequate understanding of PICF

研究者

发起方
Austin Health

相似试验